NeOnc Technologies Holdings, Inc. Common Stock (NTHI)vsNovartis AG ADR (NVS)
NTHI
NeOnc Technologies Holdings, Inc. Common Stock
$3.50
0.00%
HEALTHCARE · Cap: $90.50M
NVS
Novartis AG ADR
$156.33
+1.37%
HEALTHCARE · Cap: $291.32B
Smart Verdict
WallStSmart Research — data-driven comparison
NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NTHI
Avoid15
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for NTHI.
Margin of Safety
-66.5%
Fair Value
$92.73
Current Price
$156.33
$63.60 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
0.0% margin — thin
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : NTHI
The strongest argument for NTHI centers on Debt/Equity.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : NTHI
The primary concerns for NTHI are EPS Growth, Market Cap, Return on Equity.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 15/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
NeOnc Technologies Holdings, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
NeOnc Technologies Holdings, Inc. is a pioneering biotechnology firm dedicated to revolutionizing cancer treatment through its advanced immunotherapy and molecular medicine initiatives. The company boasts a compelling pipeline of innovative product candidates aimed at addressing critical unmet needs within oncology, which positions it as a potential leader in the evolution of cancer care. Backed by strategic partnerships within the biopharmaceutical sector, NeOnc has the capability to accelerate the commercialization of its groundbreaking therapies, presenting a compelling opportunity for institutional investors interested in the expanding cancer therapeutics market.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?